New perspectives of the treatment of migraine

MUDr. Rudolf Kotas, Ph.D.

Prakt. Lékáren. 2018; 14(1e)  

The acute treatment of migraine attacks is so far limited to the use of simple analgesics, non-steroidal anti-inflammatory drugs, ergotaminesand triptans. On the basis of our knowledge about pathophysiology of migraine, which is mentioned in this article, new medicaments for thetreatment of acute migraine attacks have been developed targeted especially to calcitonin gene–related peptide (CGRP) and serotonin 5-HT1Freceptors. Other therapeutic targets are mentioned, such as glutamate, combination of 5-HT1B/1D receptors and neuronal nitric oxide synthesisand medicament influencing cortical spreading depression. In the prophylaxis of migraine, the...

The most common drug allergy in children

MUDr. Martin Liška, Ph.D.

Prakt. Lékáren. 2018; 14(1e)  

Drug hypersensitivity reactions (DHR) affect significant portion of pediatric population. The most common immunopathogene tic mechanismsare specific IgE mediated reactions or specific T cells mediated reactions. Part of adverse drug reactions has no immunological basis. The mostfrequent drugs causing DHR are antibiotics, especially beta-lactams, further drugs causing perioperative allergic reactions, non-steroidal anti-inflammatory drugs and less frequently chemotherapeutics, contrast media or vaccines. The basis of DHR diagnosis is carefully obtainedhistory followed by skin testing, eventually drug provocation test. Optimal result of diagnostic procedure...

Beta-lactam allergy today

MUDr. Lenka Sedláčková

Prakt. Lékáren. 2018; 14(1e)  

Allergy to penicillin and other beta-lactams is the most frequently reported drug allergy. It is usually not questioned due to its known riskof severe and even fatal anaphylaxis. However, the diagnosis is often based on various symptoms in temporal connection with antibioticuse only, and is not checked any more. A complete allergy workup including a provocation test confirms a true allergy only in a smallnumber of patients. It can rid a patient of a false diagnosis and of a needless limitation of therapeutic possibilities. Its wider application inpractice is very desirable.

Evolocumab for the treatment of familial hypercholesterolemia

Vladimír Bláha

Prakt. Lékáren. 2018; 14(1e)  

Familial hypercholesterolaemia (FH) is the most common dominantly inherited monogenic disorder in human beings worldwide. Familial hypercholesterolaemiais caused by mutations in genes encoding key proteins involved in low density lipoprotein cholesterol (LDL-C) metabolism,which leads to reduced cellular uptake of LDL cholesterol, increased plasma LDL cholesterol concentrations, and premature development ofcardiovascular disease. Despite the availability of reliable diagnostic criteria (high LDL-C levels, family history or premature CHD and hypercholesterolemia,cerebral/peripheral vascular disease, and the presence of tendon xanthomata or presence of...

Střípky z XIX. sympozia klinické farmacie René Macha

Julie Strážnická, Karel Hloch, Eva Zimčíková

Prakt. Lékáren. 2018; 14(1e): e38-e48  

E-verze 1/18

Prakt. Lékáren. 2018; 14(1e)